A new life sciences fund, LSP 6, is one of the largest fundraisings in Europe in the sector, and will invest in around 15-to-18 pharma or medtech companies.
Promising news for Europe’s biotech start-ups that LSP (Life Sciences Partners) has closed its latest European life sciences fund at $600m has been tempered by estimates that the total amount of capital available to innovators in Europe is still around a fifth of that available in the US.
The LSP 6 fund, which has already backed several biotech companies in Europe over the past several months, originally targeted...
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.
The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.
